CorMedix Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
CorMedix reported Q2 2026 consolidated revenue of $101.9M (DefenCath $66.1M + Melinta portfolio $35.8M), net income of $26.0M ($0.33 basic EPS), and adjusted EBITDA of $58.7M. The company maintains FY 2026 revenue guidance of $325–$345M but raises adjusted EBITDA guidance to $125–$140M (from prior range). Key developments: signed multi-year DefenCath supply agreement with Large Dialysis Operator (LDO), now contracts all top-5 US dialysis providers; announced Q3 2026 FDA submission of REZZAYO sNDA for invasive fungal disease prophylaxis with H1 2027 expected agency action. Cash position strengthened to $256.7M.
Why this rating
Strong Q2 execution with 157% YoY revenue growth (post-Melinta acquisition), guidance raise signals confidence. All-top-5 dialysis customer footprint is material competitive positioning. However, $101.9M quarterly revenue is ~45% of company's market cap annualized; meaningful but not transformational. Event is ordinary quarterly disclosure with positive operational momentum.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.